A detailed history of Procyon Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Procyon Advisors, LLC holds 15,010 shares of VRTX stock, worth $6.77 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares
15,010
Previous 14,853 1.06%
Holding current value
$6.77 Million
Previous $6.96 Million 0.27%
% of portfolio
0.49%
Previous 0.52%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$460.0 - $505.78 $72,220 - $79,407
157 Added 1.06%
15,010 $6.98 Million
Q2 2024

Aug 02, 2024

BUY
$392.81 - $485.53 $208,189 - $257,330
530 Added 3.7%
14,853 $6.96 Million
Q1 2024

Apr 15, 2024

BUY
$407.69 - $446.08 $259,290 - $283,706
636 Added 4.65%
14,323 $5.99 Million
Q4 2023

Jan 18, 2024

BUY
$343.0 - $410.68 $322,077 - $385,628
939 Added 7.37%
13,687 $5.57 Million
Q3 2023

Oct 10, 2023

BUY
$338.18 - $362.46 $1.82 Million - $1.95 Million
5,375 Added 72.9%
12,748 $4.43 Million
Q2 2023

Jul 17, 2023

BUY
$314.42 - $351.91 $1.27 Million - $1.42 Million
4,028 Added 120.42%
7,373 $2.59 Million
Q1 2023

Apr 10, 2023

BUY
$283.23 - $323.1 $182,116 - $207,753
643 Added 23.8%
3,345 $1.05 Million
Q4 2022

Jan 19, 2023

BUY
$285.76 - $321.48 $406,922 - $457,787
1,424 Added 111.42%
2,702 $0
Q3 2022

Oct 17, 2022

SELL
$273.83 - $305.53 $24,097 - $26,886
-88 Reduced 6.44%
1,278 $370,000
Q2 2022

Jul 11, 2022

BUY
$234.96 - $292.55 $8,693 - $10,824
37 Added 2.78%
1,366 $385,000
Q1 2022

Apr 18, 2022

BUY
$221.42 - $260.97 $294,267 - $346,829
1,329 New
1,329 $347,000
Q3 2020

Oct 22, 2020

SELL
$255.65 - $303.1 $69,536 - $82,443
-272 Closed
0 $0
Q4 2019

Feb 21, 2020

BUY
$166.71 - $223.91 $45,345 - $60,903
272 New
272 $60,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Procyon Advisors, LLC Portfolio

Follow Procyon Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Procyon Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Procyon Advisors, LLC with notifications on news.